Multiple endocrine neoplasia type 2 medical therapy

Jump to navigation Jump to search

Multiple endocrine neoplasia type 2 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 2 from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Criteria

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Multiple endocrine neoplasia type 2 medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 2 medical therapy

CDC on Multiple endocrine neoplasia type 2 medical therapy

Multiple endocrine neoplasia type 2 medical therapy in the news

Blogs on Multiple endocrine neoplasia type 2 medical therapy

Directions to Hospitals Treating Multiple endocrine neoplasia type 2

Risk calculators and risk factors for Multiple endocrine neoplasia type 2 medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

The mainstay of multiple endocrine neoplasia type 2 is surgery. Medical therapies for multiple endocrine neoplasia type 2 include vandetanib, external beam radiation therapy analogues, and intensity modulated radiation therapy.

Medical Therapy

The mainstay of multiple endocrine neoplasia type 2 is surgery. Medical management of multiple endocrine neoplasia type 2 depends on the type of tumor involved.

Medullary Thyroid Cancer

Pregnancy Management

Target Therapy for Persistent Medullary Thyroid Cancer

Primary Hyperparathyroidism

Radiation Therapy

Contraindicated Medications

References

  1. Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. doi:10.1210/jc.2008-0923.
  2. Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. doi:10.1016/j.clon.2010.03.014.
  3. Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M; et al. (2012). "Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial". J Clin Oncol. 30 (2): 134–41. doi:10.1200/JCO.2011.35.5040. PMC 3675689. PMID 22025146.


Template:WikiDoc Sources